PEG Drug Conjugates With Targeting Moieties for Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PEGylated drugs face challenges in achieving effective therapeutic efficacy while minimizing toxicity and side effects, particularly in the development of small-molecule drugs and dual or multiple drug formulations.
Innovation Solution
The synthesis of novel polyethylene glycol (PEG)-based compounds with specific molecular structures, including PEG-small molecule drugs and active targeting moieties, using unique molecular design and protecting group chemistry to enhance therapeutic efficacy and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEGylation technology is used to conjugate cytotoxic drugs with small molecules, then therapeutic efficacy is improved, but side effects increase due to insufficient control over drug delivery specificity
Solution Approach 1:
The patent applies local quality by introducing active targeting moieties (such as folate, transferrin, or antibody fragments) at specific locations on the PEG-drug conjugate structure. These targeting moieties are strategically positioned to recognize and bind to specific receptors overexpressed on tumor cells, thereby localizing the cytotoxic effect to the target tissue while minimizing exposure to healthy tissues. This resolves the contradiction by maintaining high therapeutic efficacy through targeted delivery while reducing systemic side effects.
Solution Approach 2:
The patent uses the PEG polymer chain as an intermediary carrier that connects the cytotoxic drug to the small molecule or targeting moiety. This PEG spacer acts as a mediator that controls the spatial arrangement and interaction between the drug and target, allowing for optimized pharmacokinetics and reduced immunogenicity. The intermediary PEG structure enables the drug to reach the target effectively while shielding the cytotoxic moiety from premature interaction with non-target tissues, thus improving efficacy while reducing side effects.
2Manufacturing precision
If complex molecular structures with multiple functional groups are synthesized to achieve targeted delivery, then drug delivery precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs segmentation by dividing the PEG-drug conjugate into modular components: a PEG backbone, a cytotoxic drug payload, and separate active targeting moieties. Each module can be independently synthesized and characterized, then assembled through well-defined conjugation chemistries. This modular approach maintains manufacturing precision by allowing independent optimization of each component while simplifying the overall manufacturing process through standardized coupling reactions rather than requiring synthesis of entirely complex monolithic structures.
Solution Approach 2:
The patent applies universality by designing the PEG conjugate structure to perform multiple functions simultaneously: the PEG chain provides solubility and circulation half-life extension, the targeting moiety provides specificity, and the drug payload provides cytotoxic activity. This multi-functional design achieves precise drug delivery without requiring separate complex structures for each function, as the single PEG-conjugate molecule integrates all necessary functionalities, thereby reducing overall structural complexity while maintaining delivery precision.
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
The present application relates to a polyethylene glycol drug, and a preparation method therefor and the use thereof. Specifically, the present application relates to a compound as represented by formula I or a pharmaceutically acceptable salt thereof, intermediate compounds thereof as represented by formula II to formula XX, a method for preparing the compound, and the use thereof in fighting tumors. Biological tests show that the compound of the present application has a significant inhibitory effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma, osteosarcoma, etc.